269
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells

, , , , , , , , , & show all
Pages 174-183 | Received 23 Dec 2015, Accepted 28 Aug 2016, Published online: 14 Oct 2016

References

  • Araujo FD, Stracker TH, Carson CT, Lee DV, Weitzman MD. 2005. Adenovirus type 5 E4orf3 protein targets the Mre11 complex to cytoplasmic aggresomes. J Virol. 79:11382–11391.
  • Baker A, Rohleder KJ, Hanakahi LA, Ketner G. 2007. Adenovirus E4 34k and E1b 55k oncoproteins target host DNA ligase IV for proteasomal degradation. J Virol. 81:7034–7040.
  • Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD. 2003. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J. 22:6610–6620.
  • Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, et al. 2001. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 61:5453–5460.
  • Cheng CY, Gilson T, Dallaire F, Ketner G, Branton PE, Blanchette P. 2011. The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. J Virol. 85:765–775.
  • Cheng WS, Dzojic H, Nilsson B, Totterman TH, Essand M. 2006. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther. 13:13–20.
  • Ching CB, Hansel DE. 2010. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest. 90:1406–1414.
  • Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P, Yu DC. 2005. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther. 12:715–722.
  • Forrester NA, Sedgwick GG, Thomas A, Blackford AN, Speiseder T, Dobner T, Byrd PJ, Stewart GS, Turnell AS, Grand RJ. 2011. Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection. J Virol. 85:2201–2211.
  • Hart LS, Ornelles D, Koumenis C. 2007. The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage. J Biol Chem. 282:6061–6067.
  • Hartman ZC, Black EP, Amalfitano A. 2007. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology. 358:357–372.
  • Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, et al. 2008. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res. 68:9771–9778.
  • Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. 2007. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther. 15:1495–1503.
  • Jaboin JJ, Shinohara ET, Moretti L, Yang ES, Kaminski JM, Lu B. 2007. The role of mTOR inhibition in augmenting radiation induced autophagy. Technol Cancer Res Treat. 6:443–447.
  • Jacobs BL, Lee CT, Montie JE. 2010. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 60:244–272.
  • Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, et al. 2007. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res. 13:7451–7458.
  • Lee AY, Liu E, Wu X. 2007. The Mre11/Rad50/Nbs1 complex plays an important role in the prevention of DNA rereplication in mammalian cells. J Biol Chem. 282:32243–32255.
  • Lee JH, Paull TT. 2005. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 308:551–554.
  • Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE, Deweese TL, Rodriguez R. 2010. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol. 86:220–229.
  • Qian J, Yang J, Dragovic AF, Abu-Isa E, Lawrence TS, Zhang M. 2005. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Res. 65:5493–5497.
  • Rajecki M, af Hallstrom T, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI, Tenhunen M, Rantanen V, Desmond RA, Chen DT, et al. 2009. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer. 125:2441–2449.
  • Tang DC, Jennelle RS, Shi Z, Garver RI Jr, Carbone DP, Loya F, Chang CH, Curiel DT. 1997. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. Hum Gene Ther. 8:2117–2124.
  • Wang D, Wang Z, Tian J, He X, Chowdhury WH, Zhang X, Li S, Rodriguez R. 2010. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector. Urol Oncol. 28:164–169.
  • Yuan J, Chen J. 2010. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J Biol Chem. 285:1097–1104.
  • Zandvliet ML, Falkenburg JH, van Liempt E, Veltrop-Duits LA, Lankester AC, Kalpoe JS, Kester MG, van der Steen DM, van Tol MJ, Willemze R, et al. 2010. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica. 95:1943–1951.
  • Zhai Z, Wang Z, Fu S, Lu J, Wang F, Li R, Zhang H, Li S, Hou Z, Wang H, Rodriguez R. 2012. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Ther. 19:1065–1074.
  • Zhang M, Li S, Li J, Ensminger WD, Lawrence TS. 2003. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther. 8:21–28.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.